BrightPath Biotherapeutics Co., Ltd.
Status: Publicly traded
Direct answer
BrightPath Biotherapeutics Co., Ltd. is publicly traded on JPX under the ticker 4594.T.
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines;...
Can you invest in BrightPath Biotherapeutics Co., Ltd.?
Yes. BrightPath Biotherapeutics Co., Ltd. is publicly traded on JPX under the ticker 4594.T.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for BrightPath Biotherapeutics Co., Ltd.
Detailed equity research is provided by MarketSnap.